Payment overview · 2025
General Payments
$2,356.88
116 reported records · 19 companies
Healthcare provider profile · identity verified
Jose A Gonzalez, M.D.
Allopathic & Osteopathic Physicians|General Practice · HIALEAH, FL · NPI 1184697732
Verified facts
What the public records show
CMS Open Payments records show Jose A Gonzalez, M.D. received $2,356.88 in general payments during 2025 across 116 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Entresto, Farxiga, Gemtesa, Jardiance, Leqvio, Linzess, Mounjaro, Nurtec Odt, Ozempic, Prolia, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 477 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Entresto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LEQVIO as an associated drug or biological on 126702 records involving 33819 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Leqvio by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $595.61 | 25.3% | 21 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $219.10 | 9.3% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $212.38 | 9.0% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $207.54 | 8.8% | 12 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $195.62 | 8.3% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $177.23 | 7.5% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $143.84 | 6.1% | 7 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $88.56 | 3.8% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $84.56 | 3.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $79.34 | 3.4% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $70.92 | 3.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.43 | 2.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.38 | 2.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.10 | 2.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.74 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.00 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.68 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.39 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.46 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,356.88 | 116 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $327.01 | 14 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $195.62 | 10 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $177.23 | 8 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $176.67 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $169.56 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $163.90 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $162.75 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $153.72 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $146.79 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.84 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $143.84 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $136.47 | 5 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $88.56 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $76.05 | 4 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $72.31 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $70.92 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.43 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.79 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.43 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.43 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.71 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 66 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 106 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 155 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 136 | exact normalized | Medicare Part D |
| LEQVIO leqvio |
2025 | Leqvio | 2024 | 32 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 315 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 477 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 33 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 91 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 347 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
66 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
315 | 74 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
198 | 41 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
33 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
136 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
347 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
136 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
477 | 71 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
91 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
106 | 26 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | LEQVIO open payments reported associated product |
CMS Open Payments — General Payments 126702 supporting records · 33819 recipient NPIs · example record 1200004747 |
Leqvio · 2024 Exact normalized brand match · 1 Part D row |
32 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
91 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
241 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
155 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 599 | 156 |
| Montelukast Sodium | Montelukast Sodium | 577 | 100 |
| Omeprazole | Omeprazole | 545 | 105 |
| Diclofenac Sodium | Diclofenac Sodium | 497 | 109 |
| Gabapentin | Gabapentin | 487 | 103 |
| Mounjaro | Tirzepatide | 477 | 71 |
| Metformin Hcl | Metformin Hcl | 397 | 86 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 392 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 377 | 97 |
| Ibuprofen | Ibuprofen | 368 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 359 | 93 |
| Fluticasone Propionate | Fluticasone Propionate | 347 | 77 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 347 | 52 |
| Vascepa | Icosapent Ethyl | 341 | 58 |
| Linzess | Linaclotide | 315 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 67 |
| Ezetimibe | Ezetimibe | 305 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 290 | 79 |
| Famotidine | Famotidine | 284 | 70 |
| Clonidine Hcl | Clonidine Hcl | 283 | 70 |
| Meloxicam | Meloxicam | 270 | 72 |
| Losartan Potassium | Losartan Potassium | 266 | 60 |
| Alprazolam | Alprazolam | 263 | 41 |
| Dicyclomine Hcl | Dicyclomine Hcl | 260 | 65 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 247 | 68 |
| Clonazepam | Clonazepam | 241 | 52 |
| Eliquis | Apixaban | 241 | 43 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 240 | 86 |
| Ammonium Lactate | Ammonium Lactate | 239 | 48 |
| Tramadol Hcl | Tramadol Hcl | 239 | 81 |
| Clopidogrel | Clopidogrel Bisulfate | 230 | 52 |
| Temazepam | Temazepam | 217 | 34 |
| Allopurinol | Allopurinol | 209 | 47 |
| Glimepiride | Glimepiride | 208 | 50 |
| Ketoconazole | Ketoconazole | 207 | 43 |
| Donepezil Hcl | Donepezil Hcl | 206 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 45 |
| Furosemide | Furosemide | 203 | 51 |
| Synthroid | Levothyroxine Sodium | 198 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 198 | 37 |
| Meclizine Hcl | Meclizine Hcl | 187 | 49 |
| Mupirocin | Mupirocin | 187 | 76 |
| Azithromycin | Azithromycin | 182 | 120 |
| Baclofen | Baclofen | 182 | 54 |
| Levofloxacin | Levofloxacin | 182 | 135 |
| Memantine Hcl | Memantine Hcl | 170 | 49 |
| Lisinopril | Lisinopril | 165 | 46 |
| Ozempic | Semaglutide | 161 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 40 |
| Buspirone Hcl | Buspirone Hcl | 156 | 45 |
| Gemtesa | Vibegron | 155 | 33 |
| Clobetasol Propionate | Clobetasol Propionate | 152 | 46 |
| Sucralfate | Sucralfate | 151 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 146 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 31 |
| Prednisone | Prednisone | 142 | 57 |
| Alendronate Sodium | Alendronate Sodium | 141 | 32 |
| Dexlansoprazole Dr | Dexlansoprazole | 141 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 139 | 46 |
| Jardiance | Empagliflozin | 136 | 29 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 136 | 26 |
| Pregabalin | Pregabalin | 135 | 22 |
| Carvedilol | Carvedilol | 129 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 126 | 24 |
| Dutasteride | Dutasteride | 126 | 28 |
| Celecoxib | Celecoxib | 123 | 28 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 121 | 25 |
| Spironolactone | Spironolactone | 120 | 19 |
| Myrbetriq | Mirabegron | 119 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 117 | 19 |
| Diclofenac Sodium Er | Diclofenac Sodium | 116 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 110 | 29 |
| Restasis | Cyclosporine | 110 | 21 |
| Telmisartan | Telmisartan | 110 | 20 |
| Hydrocortisone | Hydrocortisone | 109 | 26 |
| Cilostazol | Cilostazol | 108 | 29 |
| Entresto | Sacubitril/Valsartan | 106 | 26 |
| Ondansetron Odt | Ondansetron | 105 | 37 |
| Ciclopirox | Ciclopirox | 104 | 35 |
| Mirtazapine | Mirtazapine | 102 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 100 | 32 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 99 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 99 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 18 |
| Bupropion Xl | Bupropion Hcl | 96 | 20 |
| Azelastine Hcl | Azelastine Hcl | 95 | 15 |
| Megestrol Acetate | Megestrol Acetate | 92 | 23 |
| Nitroglycerin | Nitroglycerin | 91 | 25 |
| Rexulti | Brexpiprazole | 91 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 88 | 19 |
| Nifedipine Er | Nifedipine | 87 | 16 |
| Sertraline Hcl | Sertraline Hcl | 87 | 17 |
| Valsartan | Valsartan | 85 | 25 |
| Xarelto | Rivaroxaban | 83 | 17 |
| Atenolol | Atenolol | 82 | 14 |
| Halobetasol Propionate | Halobetasol Propionate | 82 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 82 | 16 |
| Labetalol Hcl | Labetalol Hcl | 81 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 81 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 61 |
| Acyclovir | Acyclovir | 76 | 19 |
| Metronidazole | Metronidazole | 76 | 36 |
| Farxiga | Dapagliflozin Propanediol | 74 | 18 |
| Folic Acid | Folic Acid | 74 | 17 |
| Repaglinide | Repaglinide | 74 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 73 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 19 |
| Lidocaine | Lidocaine | 73 | 15 |
| Ofloxacin | Ofloxacin | 73 | 47 |
| Sumatriptan Succinate | Sumatriptan Succinate | 73 | suppressed |
| Lactulose | Lactulose | 72 | 30 |
| Rizatriptan | Rizatriptan Benzoate | 72 | 12 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 71 | 21 |
| Rivastigmine | Rivastigmine | 71 | 14 |
| Chlorthalidone | Chlorthalidone | 69 | 16 |
| Irbesartan | Irbesartan | 69 | 12 |
| Naproxen | Naproxen | 69 | 20 |
| Creon | Lipase/Protease/Amylase | 66 | 23 |
| Icosapent Ethyl | Icosapent Ethyl | 66 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 65 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 63 | 34 |
| Enalapril Maleate | Enalapril Maleate | 63 | 15 |
| Lorazepam | Lorazepam | 61 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 61 | suppressed |
| Nystatin | Nystatin | 61 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 27 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 57 | 49 |
| Glipizide Er | Glipizide | 55 | 12 |
| Ssd | Silver Sulfadiazine | 55 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 46 |
| Dexamethasone | Dexamethasone | 54 | 43 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 53 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 14 |
| Potassium Chloride | Potassium Chloride | 52 | 15 |
| Potassium Citrate Er | Potassium Citrate | 52 | 12 |
| Methotrexate | Methotrexate Sodium | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Tadalafil | Tadalafil | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | suppressed |
| Latanoprost | Latanoprost | 44 | suppressed |
| Topiramate | Topiramate | 44 | suppressed |
| Cyclosporine | Cyclosporine | 43 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 42 | 13 |
| Tobradex St | Tobramycin/Dexamethasone | 42 | 30 |
| Nitroglycerin Patch | Nitroglycerin | 41 | 12 |
| Praluent Pen | Alirocumab | 40 | suppressed |
| Ursodiol | Ursodiol | 40 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 31 |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Fluconazole | Fluconazole | 38 | 21 |
| Terconazole | Terconazole | 38 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Finasteride | Finasteride | 37 | 11 |
| Ibu | Ibuprofen | 37 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 37 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 14 |
| Scopolamine | Scopolamine | 36 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 32 |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 35 | suppressed |
| Budesonide Ec | Budesonide | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Pentoxifylline | Pentoxifylline | 34 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 34 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | 27 |
| Procto-Med Hc | Hydrocortisone | 33 | suppressed |
| Prolia | Denosumab | 33 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 32 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Leqvio | Inclisiran Sodium | 32 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 31 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 21 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Livalo | Pitavastatin Calcium | 26 | suppressed |
| Premarin | Estrogens, Conjugated | 26 | 14 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Erythromycin | Erythromycin Base | 24 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | 15 |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | 16 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Insulin Aspart | Insulin Aspart | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 16 | 12 |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Colchicine | Colchicine | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Benicar | Olmesartan Medoxomil | 13 | suppressed |
| Benzonatate | Benzonatate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Plavix | Clopidogrel Bisulfate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Trandolapril | Trandolapril | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Calcipotriene | Calcipotriene | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Oxazepam | Oxazepam | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,356.88 · 116 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CREON, ENTRESTO, EVENITY, FARXIGA, FREESTYLE LIBRE, GEMTESA, JARDIANCE, JOURNAVX, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error